|
KMID : 0390320230330020001
|
|
Chungbuk Medical Journal
2023 Volume.33 No. 2 p.1 ~ p.12
|
|
|
Real-world retrospective study on the current status of the electronic medical record related to anticancer drug therapy in Korean medical institutions
|
|
Han Hye-Sook
Kim Bum-Jun
Ryu Min-Hee
Park Se-Hoon
Rha Sun-Young
Kim Jong-Gwang
Bae Woo-Kyun
Lee Keun-Wook
Oh Do-Youn
Kim In-Ho
Sym Sun-Jin
Oh So-Yeon
Kim Hyeong-Su
Byun Ji-Hye
Kim Dong-Sook
Suh Young-Ju
Jee Hee-Jung
An Hyong-GIn
Zang Dae-Young
|
|
|
Abstract
|
|
|
Purpose: The electronic medical record (EMR) is the most important real-world data (RWD) for evaluating the effectiveness of anticancer drugs. In this retrospective study, we aim to analyze the format and current status of the EMR related to anticancer drug therapy in Korean medical institutions.
Patients and Methods: This study was conducted in Korean medical institutions that prescribed the combination therapy of
ramucirumab and paclitaxel under national health insurance coverage in Korea from May 1 to December 31, 2018, when national health insurance coverage began for the combination therapy of ramucirumab and paclitaxel for advanced gastric cancer. We investigated each institution’s EMR formats and recording methods, examining 76 items to evaluate the efficacy and adverse reactions associated with combination therapy of ramucirumab and paclitaxel.
Results: Fifty-five medical institutions that prescribed the combination therapy of ramucirumab and paclitaxel for advanced gastric cancer participated in this survey. Separate EMR formats were found capable of recording tumor response evaluation (Response Evaluation Criteria in Solid Tumors), adverse reactions associated with anticancer drug therapy (National Cancer Institute-Common Terminology Criteria for Adverse Events), and changes in dosage of anticancer drugs, with corresponding rates of 54.5%, 63.6%, and 49.1%, respectively. Information at the time of diagnosis of locally advanced unresectable or metastatic cancer (37.1%) and clinical information at the initiation of combination therapy of ramucirumab and paclitaxel (33.9%) had a low formatting rate. Conversely, baseline patients? characteristics (69.8%) and laboratory test results (58.6%) had relatively high formatting rates. Most data on EMR items associated with anticancer drug therapy were recorded in text format on outpatient records.
Conclusion: In the EMRs, which are associated with anticancer drug therapy of Korean medical institutions, the proportion of major items described in text form without formatting was high in the RWD collection for anticancer drugs cost-effectiveness analysis. To improve data collection accuracy, in the future, coding essential items associated with anticancer drug therapy, establishing a Common Data Model to increase the connection between EMRs of medical institutions, and promoting data sharing between medical and public institutions to collect comprehensive RWD is required.
|
|
|
KEYWORD
|
|
|
Real-world data, Medical institution, Electronic medical Anticancer drug
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|
|
|